As for the future of the industry, the report remarks “Emerging companies developing novel extracts or pure compounds and conducting early research before selling to larger players, according to a biotech model, may be representative of the future of the industry. Once a few companies are seen to be commercially successful by applying this model … a new nutraceuticals industry may really take off.”
“We are delighted that WG has been recognized as an innovator by strategic market experts. We are determined to bring value to consumers, health care professionals, and our investors by employing our technology to discover and develop safe medical food products that address major inflammatory diseases.”
If you would like to purchase this report, please contact Paul Rodrigues, global account director of Global Business Insights in the UK: Telephone: + 44 (0) 207 675 7505, Fax: + 44 (0) 207 675 7170, E-mail: prodrigues at globalbusinessinsights dot com.
For a copy of WellGen’s primer on medical foods, please contact Bob Hellauer, WellGen CFO at rhellauer at wellgen dot com.
About WellGen, Inc.
WellGen, Inc., based in North Brunswick, N.J., is a biotechnology company at the crossroads of foods and pharmaceuticals. Using the science of nutrigenomics, the company has developed Alignomx™, a proprietary bioinformatics model that uses gene expression data to determine optimal therapeutic areas for WellGen’s pipeline of proprietary natural products. Through its in-house expertise in nutrigenomics and natural product chemistry, WellGen is developing proprietary medical foods and has additionally identified several opportunities in the functional food and beverage and dietary supplement markets.
Read the full story at http://www.prweb.com/releases/2009/11/prweb3222434.htm.
Copyright©2009 Vocus, Inc.
All rights reserved